Prime Medicine (PRME) Other financing activities (2021 - 2022)
Prime Medicine (PRME) reported Other financing activities of $1.4 million for Q4 2022, up 28.91% on a YoY basis from $1.1 million in Q4 2021, and up 87.67% quarter-over-quarter from $746000.0 in Q3 2022.
Prime Medicine (PRME) Other financing activities (2021 - 2022) Analysis & Trends
Prime Medicine has reported Other financing activities for 2 years, with the latest figure at $1.4 million in Q4 2022.
- For the quarter ending Q4 2022, Other financing activities rose 28.91% year-over-year to $1.4 million; the trailing twelve-month figure through Sep 2023 stood at $1.4 million (down 62.45% YoY), and the FY2022 full-year result was $4.0 million, up 272.19% from the prior year.
- Other financing activities for Q4 2022 stood at $1.4 million, up from $746000.0 in the prior quarter.
- The five-year high for Other financing activities was $1.4 million in Q4 2022, with the low at $624000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Prime Medicine | 572.02 Mn | 572.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 1.40 Mn |
| Dec 31, 2022 | 1.40 Mn |
| Sep 30, 2022 | 746,000.00 |
| Sep 30, 2022 | 746,000.00 |
| Jun 30, 2022 | 624,000.00 |
| Jun 30, 2022 | 624,000.00 |
| Mar 31, 2022 | 1.27 Mn |
| Mar 31, 2022 | 1.27 Mn |
| Dec 31, 2021 | 1.09 Mn |
| Dec 31, 2021 | 1.09 Mn |